Stay updated on Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.

Latest updates to the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page
- Check6 days agoChange DetectedThe page shows a minor site revision label updating from v3.4.0 to v3.4.1; there are no apparent changes to the study content or user-facing information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now shows revision v3.3.4 replacing v3.3.3. This is a minor, administrative update that does not modify study details, eligibility criteria, or results; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check56 days agoChange DetectedThe page footer now includes Revision: v3.3.3, and the previous HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check78 days agoChange DetectedThe page's revision note updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check85 days agoChange DetectedThe notice about government funding and operating status has been removed from the page. This information is administrative and does not affect the study details, eligibility criteria, or contact information.SummaryDifference0.4%

- Check100 days agoChange DetectedNote added to Study Record Dates showing the last known status as reported by National Cancer Centre, Singapore on 2023-10 and marked as Verified Unknown status. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

Stay in the know with updates to Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab and Nivolumab in Nasopharyngeal Carcinoma Clinical Trial page.